NHS Expands Genetic Testing to Protect Minority Ethnic Cancer Patients
The UK's National Health Service (NHS) has implemented a groundbreaking update to its routine pre-chemotherapy genetic testing protocols to address historical disparities affecting Black and minority ethnic cancer patients. Previously, tests only screened for four DPYD gene variants prevalent in white European populations, often failing to detect risks in other groups. This oversight led to severe adverse drug reactions, including death, as patients received standard doses despite carrying harmful variants. The new protocol includes a fifth DPYD genomic variant, which is more common among people of African and minority ethnic backgrounds. This change ensures that clinicians can adjust chemotherapy starting doses to mitigate fatal risks. Prof Veline L’Esperance of the NHS Race and Health Observatory highlighted this as a tangible step toward rectifying ethnic health inequalities, moving from discussion to clinical action. Since its introduction at Manchester University NHS Foundation Trust, the updated testing has already altered treatment plans for minority patients, significantly improving safety. This initiative addresses broader systemic issues where minority patients face poorer health outcomes, longer diagnosis waits, and inadequate support compared to their white counterparts.
Wire timeline
NHS Expands Genetic Testing to Protect Minority Ethnic Cancer Patients
The UK's National Health Service (NHS) has implemented a groundbreaking update to its routine pre-chemotherapy genetic testing protocols to address historical disparities affecting Black and minority ethnic cancer patients. Previously, tests only screened for four DPYD gene variants prevalent in white European populations, often failing to detect risks in other groups. This oversight led to severe adverse drug reactions, including death, as patients received standard doses despite carrying harmful variants. The new protocol includes a fifth DPYD genomic variant, which is more common among people of African and minority ethnic backgrounds. This change ensures that clinicians can adjust chemotherapy starting doses to mitigate fatal risks. Prof Veline L’Esperance of the NHS Race and Health Observatory highlighted this as a tangible step toward rectifying ethnic health inequalities, moving from discussion to clinical action. Since its introduction at Manchester University NHS Foundation Trust, the updated testing has already altered treatment plans for minority patients, significantly improving safety. This initiative addresses broader systemic issues where minority patients face poorer health outcomes, longer diagnosis waits, and inadequate support compared to their white counterparts.
The Guardian